Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: Results from a phase II study

Endocrine-Related Cancer

Volumn 19, Issue 5, 2012, Pages 657-666

  Kvols, Larry K ^a   Oberg, Kjell E ^b   O'Dorisio, Thomas M ^c   Mohideen, Pharis ^d   De Herder, Wouter W ^e   Arnold, Rudolf ^f   Hu, Ke ^d   Zhang, Yilong ^d   Hughes, Gareth ^d   Anthony, Lowell ^g   Wiedenmann, Bertram ^h  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

^g UNIVERSITY OF KENTUCKY   (United States)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; PASIREOTIDE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOATING; CANCER GROWTH; CANCER RESISTANCE; CARCINOID SYNDROME; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; FLATULENCE; FLUSHING; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VERTIGO; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DIARRHEA; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUSHING; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; QUALITY OF LIFE; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 84867411913     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0367     Document Type: Article

References (24)

1. Adams RL, Adams IP, Lindow SW & Atkin SL 2004 Inhibition of endothelial proliferation by the somatostatin analogue SOM230. Clinical Endocrinology 61 431-436. (doi:10.1111/j.1365-2265.2004.02098.x)
2. Arnold R, Muller H, Schade-Brittinger C, Rinke A, Klose K, Barth P, Wied M, Mayer C, Aminossadati B & PROMID Study Group 2009 Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. Journal of Clinical Oncology 27 (15S) abstract 4508.
3. Boerlin V, Van Der Hoek J, Beglinger C, Poon KW, Hartmann S, Dutreix C, Kovarik JM, Bruns C, Weckbecker G, Lewis I et al. 2003 New insights on SOM230, a universal somatostatin receptor ligand. Journal of Endocrinological Investigation 26 (8 Suppl) 14-16.
4. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J et al. 2009 Treatment of pituitary dependent Cushing's disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. Journal of Clinical Endocrinology and Metabolism 94 115-122. (doi:10.1210/jc.2008-1008)
5. Bruns C, Weckbecker G, Raulf F, Kaupmann K, Schoeffter P, Hoyer D & Lubbert H 1994 Molecular pharmacology of somatostatin-receptor subtypes. Annals of the New York Academy of Sciences 733 138-146. (doi:10.1111/j.1749-6632.1994. tb17263.x)
6. Bruns C, Lewis I, Briner U, Meno-Tetang G & Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. European Journal of Endocrinology 146 707-716. (doi:10.1530/eje.0.1460707)
7. Fajans SS & Vinik AI 1989 Insulin-producing islet cell tumors. Endocrinology and Metabolism Clinics of North America 18 45-74.
8. Hofland LJ & Lamberts SW 2003 The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocrine Reviews 24 28-47. (doi:10.1210/er.2000-0001)
9. Hofland LJ, Van Der Hoek J, Feelders R, van der Lely AJ, De Herder W & Lamberts SW 2005 Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. Journal of Endocrinological Investigation 28 (11 Suppl) 36-42.
10. Lattuada D, Casnici C, Crotta K, Mastrotto C, Franco P, Schmid HA & Marelli O 2007 Inhibitory effect of pasireotide and octreotide on lymphocyte activation. Journal of Neuroimmunology 182 153-159. (doi:10.1016/j.jneuroim. 2006.10.007)
11. Li M, Li W, Kim HJ, Yao Q, Chen C & Fisher WE 2004 Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR. Journal of Surgical Research 119 130-137. (doi:10.1016/j.jss.2004.03. 006)
12. Loftus JP & van Heerden JA 1995 Surgical management of gastrointestinal carcinoid tumors. Advances in Surgery 28 317-336.
13. Long RG, Bryant MG, Mitchell SJ, Adrian TE, Polak JM & Bloom SR 1981 Clinicopathological study of pancreatic and ganglioneuroblastoma tumours secreting vasoactive intestinal polypeptide (vipomas). BMJ 282 1767-1771. (doi:10.1136/bmj.282.6278.1767)
14. Modlin IM, Kidd M, Latich I, Zikusoka MN & Shapiro MD 2005 Current status of gastrointestinal carcinoids. Gastroenterology 128 1717-1751. (doi:10.1053/j.gastro.2005.03.038)
15. Modlin IM, Latich I, Kidd M, Zikusoka M & Eick G 2006 Therapeutic options for gastrointestinal carcinoids. Clinical Gastroenterology and Hepatology 4 526-547. (doi:10.1016/j.cgh.2005.12.008)
16. Modlin IM, Pavel M, Kidd M & Gustafsson BI 2010 Review article: somatostatin analogs in the treatment of gastro-entero-pancreatic neuroendocrine (carcinoid) tumors. Alimentary Pharmacology & Therapeutics 31 169-188. (doi:10.1111/j.1365-2036.2009.04174.x)
17. Oberg K 2004 Management of neuroendocrine tumors. Annals of Oncology 15 iv293-iv298. (doi:10.1093/annonc/mdh216)
18. Ono K, Suzuki T, Miki Y, Taniyama Y, Nakamura Y, Noda Y, Watanabe M & Sasano H 2007 Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727. Anticancer Research 27 2231-2239.
19. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, Goede A, Caplin M, Oberg K, Reubi JC et al. 2004 Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80 394-424. (doi:10.1159/000085237)
20. Rinke A, Müller H-H, Schade-Brittinger C, Klose K-J, Barth P, Wied M, Mayer C, Aminossadati B, Pape U-F, Bläker M et al. 2009 Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. Journal of Clinical Oncology 27 4656-4663. (doi:10.1200/JCO.2009.22.8510)
21. Ronga G, Salerno G, Procaccini E, Mauro L, Annovazzi A, Barone R, Mellozzi M, Tamburrano G & Signore A 1995 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors. Quarterly Journal of Nuclear Medicine 39 134-136.
22. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P & Anthony L 1999 Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. Journal of Clinical Oncology 17 600-606.
23. Schmid HA & Schoeffter P 2004 Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80 (Suppl 1) 47-50. (doi:10.1159/000080741)
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 92 205-216. (doi:10.1093/jnci/92.3.205)